Alves Danilo Antonini, Machado Daisy, Melo Adriana, Pereira Rafaella Fabiana Carneiro, Severino Patrícia, de Hollanda Luciana Maria, Araújo Daniele Ribeiro, Lancellotti Marcelo
Laboratory of Biotechnology (LABIOTEC), Institute of Biology, University of Campinas (UNICAMP), Campinas, SP, Brazil.
Laboratory of Nanotechnology and Nanomedicine (LNMed), Institute of Technology and Research (ITP), Aracaju, SE, Brazil; Tiradentes University (UNIT), Aracaju, SE, Brazil.
Biomed Res Int. 2016;2016:9702129. doi: 10.1155/2016/9702129. Epub 2016 Sep 5.
Levofloxacin is a synthetic broad-spectrum antibacterial agent for oral or intravenous administration. Chemically, levofloxacin is the levorotatory isomer (L-isomer) of racemate ofloxacin, a fluoroquinolone antibacterial agent. Quinolone derivatives rapidly and specifically inhibit the synthesis of bacterial DNA. Levofloxacin has activity against a broad range of aerobic and anaerobic Gram-positive and Gram-negative bacteria. However, formulation of combined poloxamers thermoregulated (as Pluronic® F127) and levofloxacin for use in multiresistant bacterial treatment were poorly described in the current literature. Thus, the aim of the present work is to characterize poloxamers for levofloxacin controlled release and their use in the treatment of multidrug bacterial resistance. Micelles were produced in colloidal dispersions, with a diameter between 5 and 100 nm, which form spontaneously from amphiphilic molecules under certain conditions as concentration and temperature. Encapsulation of levofloxacin into nanospheres showed efficiency and enhancement of antimicrobial activity against , , and when compared with only levofloxacin. Furthermore, all formulations were not cytotoxic for NIH/3T3 cell lineage. In conclusion, poloxamers combined with levofloxacin have shown promising results, better than alone, decreasing the minimal inhibitory concentration of the studied bacterial multiresistance strains. In the future, this new formulation will be used after being tested in animal models in patients with resistant bacterial strains.
左氧氟沙星是一种用于口服或静脉给药的合成广谱抗菌剂。从化学结构上看,左氧氟沙星是氟喹诺酮类抗菌剂消旋氧氟沙星的左旋异构体(L-异构体)。喹诺酮衍生物能快速且特异性地抑制细菌DNA的合成。左氧氟沙星对多种需氧和厌氧革兰氏阳性及革兰氏阴性细菌均有活性。然而,目前文献中对用于多重耐药菌治疗的泊洛沙姆(如普朗尼克®F127)与左氧氟沙星联合制剂的描述较少。因此,本研究的目的是表征用于左氧氟沙星控释的泊洛沙姆及其在多重耐药菌治疗中的应用。胶束是在胶体分散体中产生的,直径在5至100纳米之间,在特定条件下(如浓度和温度)由两亲性分子自发形成。与单纯的左氧氟沙星相比,将左氧氟沙星包封到纳米球中显示出对[具体细菌名称1]、[具体细菌名称2]和[具体细菌名称3]的抗菌活性提高且效率更高。此外,所有制剂对NIH/3T3细胞系均无细胞毒性。总之,泊洛沙姆与左氧氟沙星联合使用已显示出有前景的结果,比单独使用更好,降低了所研究的多重耐药菌株的最低抑菌浓度。未来,这种新制剂将在动物模型中进行测试后用于耐药菌株患者。